Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

October 2, 2026

Study Completion Date

October 2, 2026

Conditions

SARS-CoV-2Influenza, HumanRespiratory Syncytial Virus InfectionsRespiratory Distress Syndrome

Interventions

DRUG

Placebo comparator

A single dose of saline solution 0.9% for infusion

DRUG

PRS CK STORM

A single dose of PRS CK STORM (dose A) for infusion

DRUG

PRS CK STORM

A single dose of PRS CK STORM (dose B) for infusion.

Trial Locations (1)

RECRUITING

Hospital Universitario de Fuenlabrada, Fuenlabrada

All Listed Sponsors

lead

PEACHES BIOTECH

INDUSTRY